Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Integra Lifesciences Holdings stock

IART
US4579852082
897013

Price

17.00
Today +/-
+0.05
Today %
+0.29 %
P

Integra Lifesciences Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Integra Lifesciences Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Integra Lifesciences Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Integra Lifesciences Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Integra Lifesciences Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Integra Lifesciences Holdings Stock Price History

DateIntegra Lifesciences Holdings Price
10/4/202417.00 undefined
10/3/202416.95 undefined
10/2/202417.32 undefined
10/1/202417.50 undefined
9/30/202418.17 undefined
9/27/202417.87 undefined
9/26/202417.47 undefined
9/25/202417.14 undefined
9/24/202417.88 undefined
9/23/202417.54 undefined
9/20/202417.40 undefined
9/19/202417.47 undefined
9/18/202417.53 undefined
9/17/202417.16 undefined
9/16/202417.32 undefined
9/13/202417.47 undefined
9/12/202417.65 undefined
9/11/202417.60 undefined
9/10/202417.72 undefined
9/9/202417.57 undefined

Integra Lifesciences Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Integra Lifesciences Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Integra Lifesciences Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Integra Lifesciences Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Integra Lifesciences Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Integra Lifesciences Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Integra Lifesciences Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Integra Lifesciences Holdings’s growth potential.

Integra Lifesciences Holdings Revenue, EBIT and net profit per share

DateIntegra Lifesciences Holdings RevenueIntegra Lifesciences Holdings EBITIntegra Lifesciences Holdings Net Income
2027e1.98 B undefined521.32 M undefined402.78 M undefined
2026e1.83 B undefined335.31 M undefined216.27 M undefined
2025e1.75 B undefined324.86 M undefined198.3 M undefined
2024e1.64 B undefined304.68 M undefined193.82 M undefined
20231.54 B undefined271.78 M undefined67.74 M undefined
20221.56 B undefined293.1 M undefined180.6 M undefined
20211.54 B undefined278 M undefined169.1 M undefined
20201.37 B undefined218.8 M undefined133.9 M undefined
20191.52 B undefined259.8 M undefined50.2 M undefined
20181.47 B undefined233.3 M undefined60.8 M undefined
20171.19 B undefined177.7 M undefined64.7 M undefined
2016992.1 M undefined159.5 M undefined74.6 M undefined
2015882.7 M undefined136.8 M undefined-3.5 M undefined
2014796.7 M undefined126.7 M undefined34 M undefined
2013836.2 M undefined36.5 M undefined-21.1 M undefined
2012830.9 M undefined113.9 M undefined41.2 M undefined
2011780.1 M undefined79.6 M undefined28 M undefined
2010732.1 M undefined106 M undefined65.7 M undefined
2009682.5 M undefined97.8 M undefined51 M undefined
2008654.6 M undefined47.4 M undefined27.7 M undefined
2007550.5 M undefined67.3 M undefined25.3 M undefined
2006419.3 M undefined58.7 M undefined29.4 M undefined
2005277.9 M undefined56.1 M undefined37.2 M undefined
2004229.8 M undefined24.8 M undefined17.2 M undefined

Integra Lifesciences Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
00000.010.010.010.010.020.040.070.090.120.190.230.280.420.550.650.680.730.780.830.840.80.880.991.191.471.521.371.541.561.541.641.751.831.98
--100.00100.00100.0025.0030.007.6921.43147.0669.0530.9925.8158.1223.7820.9651.2631.2618.914.287.336.566.410.72-4.7810.8012.4719.7623.913.06-9.6212.470.97-1.036.686.274.648.53
---50.0050.0050.0046.1550.0058.8247.6259.1561.2961.5462.1661.5761.3759.9060.9161.3164.0863.2561.5464.1060.8964.2064.9766.6365.4063.5264.4764.5563.3663.0763.08----
0002456710204257721151411702513354014374634805325095115736617779359788859779829720000
000-2-2-5-9-18-14-12-111419392456586747971067911336126136159177233259218278293271304324335521
----50.00-25.00-50.00-69.23-128.57-82.35-28.57-15.4915.0516.2421.0810.4820.2213.8412.187.1914.2214.4810.1313.614.3115.8315.4216.0314.9015.8317.0715.9018.0318.8217.5918.4918.5518.3326.26
000-23-1-25-7-17-12-6-17253526173729252751652841-2134-37464605013316918067193198216402
-----95.652,400.00-72.00142.86-29.41-50.00183.33-247.0640.00-25.71-34.62117.65-21.62-13.798.0088.8927.45-56.9246.43-151.22-261.90-108.82-2,566.67-13.51-6.25-16.67166.0027.076.51-62.78188.062.599.0986.11
14.514.514.516.61921.128.129.632.333.635.155.661.466.262.269.165.558.756.858.660.3595756.865.96979.279.18486.585.285.583.580.340000
--------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Integra Lifesciences Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Integra Lifesciences Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                             
5.13.35.734.326.320.223.615.166.798.9108.5100.8127.222.757.3183.571.9128.8100.896.9120.671.748.1102.1174.9138.8198.9470.2513.4456.7309.1
0.81.51.82.92.83.18.413.11419.428.946.84985103.5112.4103.2106118.1114.9118.1110.4132.2148.2251.8265.7275.3233243.2273.6259.33
0000000000000000000000000000000
0.70.91.42.62.42.710.116.524.328.54155.967.594.4144.5146.1140.2146.9171.3171.8206.9189.1211.4217.3296.3280.3316.1310.1317.4324.6389.61
0.10.40.50.30.40.90.71.52.95.513.112.722.219.634.655.35063.262.169.475.515846.727.799.190.267.922479.6106.7100.01
0.010.010.010.040.030.030.040.050.110.150.190.220.270.220.340.50.370.440.450.450.520.530.440.50.820.780.861.241.151.161.06
37.19.68.66.46.39.711.611.716.620.125.527.542.661.77683.599.5131.4177.9200.3193.6205.2222.4269.3300.1431.9371.2396.2459.6496.38
0000000064.333.598.295.216.2000000000000000000
0000000000000000000000000000000
0000000.010.020.020.020.050.060.060.180.20.230.210.190.240.210.20.410.60.561.161.081.030.991.151.131.07
00000000.010.010.020.030.040.070.160.210.210.260.260.290.290.250.360.510.510.940.930.950.931.011.041.06
00000.100.53.412.127.223.520.85.97.213.114.518.21830.426.323.888.414.418.722.326.727.38573.4103.2104.27
00.010.010.010.010.010.020.040.120.120.220.240.180.390.480.530.570.570.690.710.671.061.341.312.392.332.452.382.632.732.72
0.010.010.020.050.040.030.070.090.230.270.410.460.450.610.821.030.941.021.141.161.191.591.771.813.213.113.33.623.783.893.78
                                                             
0.20.20.20.30.20.210.50.20.30.30.30.30.30.30.30.30.40.40.40.40.40.40.50.80.80.90.90.90.90.90.91
0.030.040.070.110.110.120.120.160.280.290.290.320.330.370.40.50.520.550.610.590.750.781.020.80.821.191.211.291.261.281.3
-24.2-26.1-51.5-59-75.9-88.3-94.3-105.7-79.6-44.3-17.5-0.336.966.398.2116.2167.2232.8260.8302281315145.9220.4285.2348.4398.6532.3698.6879.1946.86
000-0.3-0.3-0.2-0.2-0.6-0.80.64.27.5-48.1195.48.9-1.8-9.1-4.80.9-23.5-47.9-57.2-23.8-45.4-76.4-74.1-45.210.3-15.11
00000000200900100-800-800000000000000000000
00.010.020.050.040.030.040.050.20.250.270.330.370.440.510.620.70.780.860.881.031.071.120.961.081.51.541.751.922.172.24
0.10.30.30.20.50.613.42.93.87.910.2920.323.22324.627.827.736.750.828.934.829.19476.1113.154.661.8102.192.33
0.4100.202.25.55.15.69.411.913.121.529.845.648.751.361.269.764.862.873.684.387.7161.1160.2168.4183.1227.9173.4191.58
2.71.31.51.81.80.263.77.18.70.810.84.32.93.14.14.44.55.45.919.95.76.833.83.84.8175.37.38.54
0000000000000000000000000000000
0000002.38.93.60000219.512010076.8108.40003.814.406022.545146.34538.114.53
3.22.61.82.22.3314.821.119.221.920.624.331.3273.9191.7174.8156.8201.8101.9106.9119.5126.2139.2123.6348.9262.6331.3401340320.9306.98
0000000.010000.120.120.1200.330.460.310.290.530.520.390.630.70.671.781.331.31.411.51.411.49
0000000.41.800002.531.416.109.310.65.75.42.1100.4154.9148.965.157.836.616.245.863.335.32
0.40.10.10.10.20.35.55.14.45.24.15.86.411.619.919.520.411.811.61412.530.428.630.753.880215.6274.8210.6295.9366.79
0000000.010.0100.010.120.120.130.040.370.480.340.320.550.540.410.760.880.841.91.471.561.71.761.761.89
0.01000000.030.030.020.030.140.150.160.320.560.650.50.520.650.650.530.881.020.972.251.731.892.12.12.092.19
0.010.010.020.050.040.040.070.090.230.280.420.480.520.761.071.281.191.31.511.531.561.952.141.933.333.233.423.854.024.254.43
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Integra Lifesciences Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Integra Lifesciences Holdings's financial health and stability.

Assets

Integra Lifesciences Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Integra Lifesciences Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Integra Lifesciences Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Integra Lifesciences Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0-23-1-25-7-17-12-6-11263526173729252751652841-2134-37464605013316918067
000111135657911192530393950524746587288110109116119118123
0000000-10-12-1312693-18-330411-13-60-6-67-8-19-64-2-4-11
00-1-1-10111-11-50-14-20-4-2-20-418-19-15-23-27-40-10-11-11-14-4118-39-81
020019060-412043263223485493266-37761754515512678443762
000000000001238101711813129100032584847434244
0000000000111716384120231412760014101629493523
0-1-3-5-8-7-92-51532343956714772143105104595379104116114199231203312264139
0-1-3-2-10-1-2-3-2-2-5-8-8-11-22-13-27-37-38-69-47-38-33-47-43-77-134-63-48-47-66
0-1-36-21-290-14-94-49-12812-30-142-123-100-88-42-190-79-50-363-372-42-1,221-49-162-68-161-58-94
0009-20-1102-11-91-47-12321-22-131-100-86-60-5-152-10-2-325-3384-1,17728-28-4-113-11-27
00000000000000000000000000000000
00-00000-00-0.01-00.120-00.10.230.14-0.180.020.160.01-0.140.230.08-0.021.19-0.49-0.010.2-0.1-0.110.05
0571360312131231-21-8-47-54-66116-15-510154152271093596-506-119-270
00.010.0100.04000.010.010.11-00.09-0.01-0.050.050.110.15-0.17-00.060.010.020.240.25-0.021.17-0.18-0.010.12-0.1-0.25-0.23
000000000000001-5510-3-5030-1-55-9-30-51-6-29-5-24-13
00000000000000000000000000000000
13-117-9314-530-19143-22-2434126-11156-28-323-48-235472-366027143-56-180
-0.5-2.8-6.8-8.5-9.2-8.7-110.2-8.312.829.729.530.548.760.224.459.2115.668.565.9-9.95.441.271.569.17112296.9139.9264.3217.473.09
00000000000000000000000000000000

Integra Lifesciences Holdings stock margins

The Integra Lifesciences Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Integra Lifesciences Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Integra Lifesciences Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Integra Lifesciences Holdings's sales revenue. A higher gross margin percentage indicates that the Integra Lifesciences Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Integra Lifesciences Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Integra Lifesciences Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Integra Lifesciences Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Integra Lifesciences Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Integra Lifesciences Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Integra Lifesciences Holdings Margin History

Integra Lifesciences Holdings Gross marginIntegra Lifesciences Holdings Profit marginIntegra Lifesciences Holdings EBIT marginIntegra Lifesciences Holdings Profit margin
2027e63.09 %26.26 %20.29 %
2026e63.09 %18.33 %11.82 %
2025e63.09 %18.6 %11.35 %
2024e63.09 %18.52 %11.78 %
202363.09 %17.63 %4.39 %
202263.04 %18.82 %11.59 %
202163.34 %18.02 %10.96 %
202064.55 %15.95 %9.76 %
201964.45 %17.12 %3.31 %
201863.54 %15.84 %4.13 %
201765.46 %14.96 %5.45 %
201666.72 %16.08 %7.52 %
201564.98 %15.5 %-0.4 %
201464.2 %15.9 %4.27 %
201360.89 %4.36 %-2.52 %
201264.14 %13.71 %4.96 %
201161.65 %10.2 %3.59 %
201063.37 %14.48 %8.97 %
200964.12 %14.33 %7.47 %
200861.38 %7.24 %4.23 %
200761 %12.23 %4.6 %
200659.86 %14 %7.01 %
200561.5 %20.19 %13.39 %
200461.49 %10.79 %7.48 %

Integra Lifesciences Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Integra Lifesciences Holdings earnings per share therefore indicates how much revenue Integra Lifesciences Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Integra Lifesciences Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Integra Lifesciences Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Integra Lifesciences Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Integra Lifesciences Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Integra Lifesciences Holdings Revenue, EBIT and net profit per share

DateIntegra Lifesciences Holdings Sales per ShareIntegra Lifesciences Holdings EBIT per shareIntegra Lifesciences Holdings Earnings per Share
2027e25.59 undefined0 undefined5.19 undefined
2026e23.58 undefined0 undefined2.79 undefined
2025e22.52 undefined0 undefined2.56 undefined
2024e21.2 undefined0 undefined2.5 undefined
202319.19 undefined3.38 undefined0.84 undefined
202218.66 undefined3.51 undefined2.16 undefined
202118.04 undefined3.25 undefined1.98 undefined
202016.1 undefined2.57 undefined1.57 undefined
201917.54 undefined3 undefined0.58 undefined
201817.53 undefined2.78 undefined0.72 undefined
201715.02 undefined2.25 undefined0.82 undefined
201612.53 undefined2.01 undefined0.94 undefined
201512.79 undefined1.98 undefined-0.05 undefined
201412.09 undefined1.92 undefined0.52 undefined
201314.72 undefined0.64 undefined-0.37 undefined
201214.58 undefined2 undefined0.72 undefined
201113.22 undefined1.35 undefined0.47 undefined
201012.14 undefined1.76 undefined1.09 undefined
200911.65 undefined1.67 undefined0.87 undefined
200811.52 undefined0.83 undefined0.49 undefined
20079.38 undefined1.15 undefined0.43 undefined
20066.4 undefined0.9 undefined0.45 undefined
20054.02 undefined0.81 undefined0.54 undefined
20043.69 undefined0.4 undefined0.28 undefined

Integra Lifesciences Holdings business model

Integra Lifesciences Holdings Corp is a multinational manufacturer and provider of medical devices, implants, and instruments. The company is headquartered in Plainsboro, New Jersey and was founded in 1989. Integra Lifesciences specializes in the development and marketing of products for orthopedic surgery, neurosurgery, and plastic and reconstructive surgery. The company has a wide range of products that have been constantly improved and expanded over the years. The history of Integra Lifesciences is characterized by continuous expansion through the acquisition of other companies. In 1996, the company acquired Confluent Surgical, which allowed them to enter the tissue adhesive sector. In the following years, several companies were acquired, including Depuy Orthopaedics, Kaye Surgical, and SeaSpine Holdings. Each acquisition has contributed to Integra Lifesciences being able to offer its customers an extensive product portfolio that meets all requirements. Integra Lifesciences has a diversified business model that focuses on four different divisions: anesthesia, neurosurgery, plastic and reconstructive surgery, and orthopedic surgery. Each division has its own range of products that are tailored to the specific requirements of its customers. Integra Lifesciences supplies high-quality medical instruments that are valued by surgeons around the world. These include products such as bone cement, implants, skull plates, bone screws, tissue adhesives, and spinal fusion devices. All products from Integra Lifesciences aim to improve patient care and enhance patients' quality of life. The anesthesia division offers a wide range of products and technologies that improve the administration of anesthesia and enable optimal patient care. In addition to traditional products such as anesthesia masks and tubes, Integra Lifesciences also develops innovative products such as disposable ventilation systems that can increase safety and efficiency. The neurosurgery division offers a wide range of devices and implants for the treatment of brain and spinal cord conditions. The product range includes skull plates, bone connectors, and devices for performing brain surgeries. In the plastic and reconstructive surgery division, Integra Lifesciences offers products for the treatment of burns and the reconstruction of bones and soft tissues. The company has a wide range of products, including skin grafts, scar treatment, and liposuction. Orthopedic surgery is one of the established divisions at Integra Lifesciences, offering a wide range of products for the treatment of bone and joint problems. The company provides implants and instruments for all types of orthopedic procedures, including hip and knee replacements, spinal fusion, and limb reconstruction. Overall, Integra Lifesciences Holdings Corp is a leading manufacturer of medical devices, implants, and instruments specializing in the fields of orthopedics, neurosurgery, and plastic and reconstructive surgery. With its comprehensive product range and innovative technologies, Integra Lifesciences has gained a leading position in the industry, providing its customers worldwide with the highest quality and safety. Integra Lifesciences Holdings is one of the most popular companies on Eulerpool.com.

Integra Lifesciences Holdings Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Integra Lifesciences Holdings Revenue by Segment

Segmente20232022202120202019201820172016
Neurosurgery818.1 M USD794.02 M USD802.96 M USD716.34 M USD----
Wound Reconstruction and Care373.99 M USD406.69 M USD392.46 M USD-----
Instruments240.89 M USD225.55 M USD222.27 M USD178.49 M USD----
Private Label108.59 M USD131.41 M USD124.75 M USD105.68 M USD108.53 M USD106.36 M USD--
Wound Reconstruction---293.04 M USD----
Extremity Orthopedics---78.32 M USD----
Orthopedics--------
Neurosurgery----707.01 M USD684.15 M USD--
Wound Reconstruction----322.74 M USD305.47 M USD--
Precision Tools and Instruments----289.2 M USD279.78 M USD--
Extremity Orthopedics----90.08 M USD96.69 M USD--
Orthopedics and Tissue Technologies----521.35 M USD508.51 M USD--
Codman Specialty Surgical1.06 B USD1.02 B USD1.03 B USD894.83 M USD996.21 M USD963.93 M USD720.3 M USD-
Tissue Technologies482.58 M USD538.1 M USD517.22 M USD-----
Orthopedics and Tissue Technologies---477.04 M USD--467.94 M USD359.55 M USD
Specialty Surgical Solutions-------632.52 M USD

Integra Lifesciences Holdings Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Integra Lifesciences Holdings Revenue by Segment

DateAsia PacificEuropeRest of the WorldUnited StatesUnited States (Includes long-lived assets in Puerto Rico)
2023193.1 M USD165.22 M USD82.53 M USD-1.1 B USD
2022176.48 M USD170.9 M USD83.48 M USD-1.13 B USD
2021182.03 M USD191.33 M USD79.56 M USD-1.09 B USD
2020157.17 M USD172.69 M USD70.03 M USD-971.98 M USD
2019157.39 M USD197.47 M USD85.32 M USD-1.08 B USD
2018144.25 M USD201.35 M USD80.95 M USD-1.05 B USD
2017-150.15 M USD143.83 M USD-894.26 M USD
2016-120.59 M USD105.88 M USD765.61 M USD-
2011---593.04 M USD-

Integra Lifesciences Holdings SWOT Analysis

Strengths

Integra Lifesciences Holdings Corp has a diverse product portfolio, catering to various medical needs and specialty segments. This allows the company to mitigate risks and maintain a stable revenue stream.

With a strong focus on research and development, Integra Lifesciences continually introduces innovative products, enhancing its competitive advantage and establishing itself as a leader in the industry.

The company has a global presence, with a wide distribution network, enabling it to reach a large customer base and generate significant sales.

Weaknesses

Integra Lifesciences heavily relies on third-party suppliers for key components and raw materials, which may expose the company to supply chain disruptions and impact production capabilities.

The company's high dependence on regulatory approvals for new product launches can cause delays and hinder its ability to quickly enter new markets.

Integra Lifesciences has faced criticism related to product recalls and quality control issues. These incidents can damage the company's reputation and customer trust.

Opportunities

The growing global healthcare industry presents Integra Lifesciences with opportunities to expand its product offerings and tap into emerging markets.

Advancements in technology offer the company potential for developing and introducing new, more efficient medical devices and solutions that meet evolving customer needs.

Strategic partnerships or acquisitions can help Integra Lifesciences strengthen its market position, gain access to new technologies, and expand its geographic presence.

Threats

Intense competition within the medical technology industry poses a threat to Integra Lifesciences. Competitors with similar product offerings and established market presence can potentially capture market share.

Changing regulations and reimbursement policies in the healthcare sector may impact the pricing and reimbursement of Integra Lifesciences' products, affecting its profitability.

Global economic uncertainties, such as recessions or currency fluctuations, can affect the purchasing power of customers and consequently impact the demand for Integra Lifesciences' products.

Integra Lifesciences Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Integra Lifesciences Holdings historical P/E ratio, EBIT multiple, and P/S ratio

Integra Lifesciences Holdings shares outstanding

The number of shares was Integra Lifesciences Holdings in 2023 — This indicates how many shares 80.337 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Integra Lifesciences Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Integra Lifesciences Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Integra Lifesciences Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Integra Lifesciences Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Integra Lifesciences Holdings stock splits

In Integra Lifesciences Holdings's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Integra Lifesciences Holdings.

Integra Lifesciences Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.64 0.63  (-0.79 %)2024 Q2
3/31/20240.56 0.55  (-2.26 %)2024 Q1
12/31/20230.92 0.89  (-3.39 %)2023 Q4
9/30/20230.79 0.76  (-4.22 %)2023 Q3
6/30/20230.58 0.71  (22.31 %)2023 Q2
3/31/20230.75 0.74  (-1.54 %)2023 Q1
12/31/20220.92 0.94  (2.05 %)2022 Q4
9/30/20220.73 0.86  (17.2 %)2022 Q3
6/30/20220.81 0.81  (-0.43 %)2022 Q2
3/31/20220.69 0.74  (6.67 %)2022 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Integra Lifesciences Holdings stock

Eulerpool World ESG Rating (EESG©)

66/ 100

🌱 Environment

45

👫 Social

71

🏛️ Governance

81

Environment

Scope 1 - Direct Emissions
13,215
Scope 2 - Indirect emissions from purchased energy
16,210
Scope 3 - Indirect emissions within the value chain
158,981
Total CO₂ emissions
29,425
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees48
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies✅
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Integra Lifesciences Holdings shareholders

%
Name
Stocks
Change
Date
9.01858 % The Vanguard Group, Inc.6,996,613-147,06112/31/2023
7.57844 % BlackRock Institutional Trust Company, N.A.5,879,352-219,32912/31/2023
5.53922 % Capital Research Global Investors4,297,3261,228,99612/31/2023
4.10582 % Wellington Management Company, LLP3,185,293151,34412/31/2023
3.81013 % Boston Management and Research2,955,898-37,87812/31/2023
3.65378 % Cooke & Bieler, L.P.2,834,604120,41012/31/2023
3.51315 % AllianceBernstein L.P.2,725,502-67,32912/31/2023
3.18929 % ClearBridge Investments, LLC2,474,249-267,67312/31/2023
3.13993 % Champlain Investment Partners, LLC2,435,957-2,87212/31/2023
2.72721 % State Street Global Advisors (US)2,115,767-21,79412/31/2023
1
2
3
4
5
...
10

Integra Lifesciences Holdings Executives and Management Board

Mr. Jan De Witte59
Integra Lifesciences Holdings President, Chief Executive Officer, Director (since 2021)
Compensation 9.32 M
Mr. Eric Schwartz54
Integra Lifesciences Holdings Executive Vice President, Chief Legal Officer, Secretary
Compensation 3.4 M
Mr. Michael Mcbreen57
Integra Lifesciences Holdings Executive Vice President and President - Codman Specialty Surgical
Compensation 2.15 M
Mr. Robert Davis64
Integra Lifesciences Holdings Executive Vice President, President - Tissue Technologies
Compensation 1.93 M
Dr. Stuart Essig61
Integra Lifesciences Holdings Independent Chairman of the Board (since 1997)
Compensation 400,034
1
2
3
4

Integra Lifesciences Holdings Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Medcom Tech Stock
Medcom Tech
SupplierCustomer0,800,700,490,13--
Navigator Stock
Navigator
SupplierCustomer0,680,64-0,62-0,70-0,660,36
Covetrus Inc Stock
Covetrus Inc
SupplierCustomer0,580,230,430,630,620,15
Lisi Stock
Lisi
SupplierCustomer0,430,520,760,720,630,77
Model N Stock
Model N
SupplierCustomer-0,360,350,390,570,81-0,11
1

Most common questions regarding Integra Lifesciences Holdings

What values and corporate philosophy does Integra Lifesciences Holdings represent?

Integra Lifesciences Holdings Corp represents a set of values and a corporate philosophy that focuses on making a positive impact in the field of healthcare. The company is committed to delivering innovative solutions and technologies, aiming to improve patient outcomes and quality of life. Integra Lifesciences Holdings Corp is guided by principles of integrity, transparency, and collaboration, fostering strong partnerships with healthcare professionals and stakeholders. With a dedication to continuous improvement, the company strives to provide advanced medical devices, regenerative technologies, and specialty products that enhance the lives of patients worldwide. Integra Lifesciences Holdings Corp prioritizes patient-centricity and is dedicated to making a difference in the global healthcare community.

In which countries and regions is Integra Lifesciences Holdings primarily present?

Integra Lifesciences Holdings Corp is primarily present in various countries and regions worldwide. These include the United States, Europe, Asia-Pacific, and Latin America.

What significant milestones has the company Integra Lifesciences Holdings achieved?

Integra Lifesciences Holdings Corp has attained several significant milestones. The company achieved FDA clearance for its DermaTran wound dressing, providing advanced wound care solutions. Additionally, Integra Lifesciences received CE Mark approval for its CUSA Clarity Ultrasonic Surgical Aspirator, enhancing surgical precision and patient outcomes. The company also introduced Codman Enterprise 2 Coil System, an advancement in endovascular treatment for brain aneurysms. Furthermore, Integra Lifesciences acquired Medtronic's MicroFrance and Xomed Surgical Products business units, broadening its product portfolio and market presence. These achievements reflect Integra Lifesciences' commitment to innovation, improving patient care, and expanding its global reach.

What is the history and background of the company Integra Lifesciences Holdings?

Integra Lifesciences Holdings Corp is a renowned global medical device company specializing in advanced surgical instruments and regenerative technologies. Established in 1989, the company has steadily evolved to become a leader in providing innovative solutions for neurosurgery, orthopedics, reconstructive surgery, and wound and tissue management. With a focus on improving patient outcomes, Integra Lifesciences develops and markets a diverse portfolio of products, ranging from implants and implants systems to surgical instruments and medical devices. Throughout its history, Integra Lifesciences has demonstrated a commitment to research, development, and collaboration, continuously enhancing its offerings to meet the evolving needs of healthcare professionals worldwide.

Who are the main competitors of Integra Lifesciences Holdings in the market?

The main competitors of Integra Lifesciences Holdings Corp in the market include Medtronic, Johnson & Johnson, Stryker Corporation, and Baxter International Inc.

In which industries is Integra Lifesciences Holdings primarily active?

Integra Lifesciences Holdings Corp is primarily active in the healthcare and medical device industries.

What is the business model of Integra Lifesciences Holdings?

The business model of Integra Lifesciences Holdings Corp is focused on providing innovative medical technologies and solutions that address various healthcare needs. The company operates in three primary segments: Codman Specialty Surgical, Orthopedics and Tissue Technologies, and Neurosurgery. Integra Lifesciences aims to enhance patient outcomes by developing and manufacturing medical devices, implants, instruments, and regenerative products. The company's comprehensive portfolio encompasses products for various medical specialties, including neurosurgery, plastic and reconstructive surgery, orthopedics, and wound care. Integra Lifesciences collaborates with healthcare professionals to offer cutting-edge solutions that improve the quality and efficiency of patient care.

What is the P/E ratio of Integra Lifesciences Holdings 2024?

The Integra Lifesciences Holdings P/E ratio is 7.05.

What is the P/S ratio of Integra Lifesciences Holdings 2024?

The Integra Lifesciences Holdings P/S ratio is 0.83.

What is the AlleAktien quality score of Integra Lifesciences Holdings?

The AlleAktien quality score for Integra Lifesciences Holdings is 5/10.

What is the revenue of Integra Lifesciences Holdings 2024?

The expected Integra Lifesciences Holdings revenue is 1.64 B USD.

How high is the profit of Integra Lifesciences Holdings 2024?

The expected Integra Lifesciences Holdings profit is 193.82 M USD.

What is the business model of Integra Lifesciences Holdings

Integra Lifesciences Holdings Corp is a leading company in the field of medical devices and instruments. It offers a wide range of products and services tailored to the needs of the healthcare industry. The company operates in three main divisions: neurosurgery, plastic & reconstructive surgery, and orthopedics & cell therapy. The neurosurgery division offers a variety of products and services tailored to the needs of neurosurgeons and patients. Integra Lifesciences Holdings Corp develops and produces innovative solutions for the treatment of neurological disorders such as Parkinson's disease. The products include the neuromodulatory system, brain stimulation device, and other technologies that help treat neurological disorders. The plastic & reconstructive surgery division offers solutions for reconstructive and aesthetic surgery. The product range includes a variety of implants, tissue grafts, bone substitutes, and other products tailored to the needs of surgeons. The company works closely with doctors to provide innovative solutions that improve patients' lives. The orthopedics & cell therapy division offers products and services tailored to the needs of orthopedic surgeons and patients. The range includes a wide range of products, such as artificial joints and bone grafts. Integra Lifesciences Holdings Corp also offers innovative cell therapy solutions. In addition to the mentioned divisions, other products are available, such as maggot cultures for wound therapy. The company places great emphasis on quality and research. It continuously invests in research and development and works closely with doctors and researchers to provide innovative solutions. Integra Lifesciences Holdings Corp has a broad customer base throughout Europe and North America and works closely with doctors, clinics, and hospitals to ensure the best possible patient care. Overall, Integra Lifesciences Holdings Corp offers innovative and individual solutions in the specialized field of healthcare through its wide range of products and research.

What is the Integra Lifesciences Holdings dividend?

Integra Lifesciences Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Integra Lifesciences Holdings pay dividends?

The dividend cannot currently be calculated for Integra Lifesciences Holdings or the company does not pay out a dividend.

What is the Integra Lifesciences Holdings ISIN?

The ISIN of Integra Lifesciences Holdings is US4579852082.

What is the Integra Lifesciences Holdings WKN?

The WKN of Integra Lifesciences Holdings is 897013.

What is the Integra Lifesciences Holdings ticker?

The ticker of Integra Lifesciences Holdings is IART.

How much dividend does Integra Lifesciences Holdings pay?

Over the past 12 months, Integra Lifesciences Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Integra Lifesciences Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Integra Lifesciences Holdings?

The current dividend yield of Integra Lifesciences Holdings is .

When does Integra Lifesciences Holdings pay dividends?

Integra Lifesciences Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Integra Lifesciences Holdings?

Integra Lifesciences Holdings paid dividends every year for the past 0 years.

What is the dividend of Integra Lifesciences Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Integra Lifesciences Holdings located?

Integra Lifesciences Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Integra Lifesciences Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Integra Lifesciences Holdings from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.

When did Integra Lifesciences Holdings pay the last dividend?

The last dividend was paid out on 10/6/2024.

What was the dividend of Integra Lifesciences Holdings in the year 2023?

In the year 2023, Integra Lifesciences Holdings distributed 0 USD as dividends.

In which currency does Integra Lifesciences Holdings pay out the dividend?

The dividends of Integra Lifesciences Holdings are distributed in USD.

All fundamentals about Integra Lifesciences Holdings

Our stock analysis for Integra Lifesciences Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Integra Lifesciences Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.